Newsroom | 54268 results

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall Clinical Dermatology Conference, taking place from October 08-11 in Las Vegas, United States. This includes a new post-hoc analysis from the ARCADIA LTE study showing that in adults and adolescents aged 12 and older who achieved an early response at Week 16 in the AR...

BARCELONA, España--(BUSINESS WIRE)--INBRAIN Neuroelectronics, una empresa de neurotecnología en fase clínica dedicada al desarrollo de terapias basadas en el grafeno para interfaces cerebro-ordenador (BCI), ha anunciado hoy la finalización con éxito y los resultados de MINIGRAPH (implante de neuromodulación mínimamente invasivo y procedimiento de implantación basados en la innovadora tecnología GRAPHene para el tratamiento de trastornos cerebrales), un proyecto financiado por el Consejo Europeo...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science ModelsTM to help predict clinical trial outcomes. IQVIA Life Science Models are a suite of purpose-built models for life sciences, combining IQVIA’s proprietary expert content, deep domain knowledge and established regulatory, com...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sigh...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance...

BALTIMORE--(BUSINESS WIRE)--Pearl Diagnostics (PearlDX), a company pioneering a new generation of non-invasive tests for lung infections, today announced the publication of clinical studies supporting U.S. Food and Drug Administration (FDA) 510(k) clearance of the MycoMEIA® Aspergillus Assay in the peer-reviewed journal Clinical Infectious Diseases. The studies evaluated the urine-based assay as an aid to diagnose invasive aspergillosis (IA), a potentially life-threatening fungal infection in p...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update outlined a defined path to completing the FDA-aligned pivotal Phase 2 trial, highlighted sustained biological activity in longer-term Phase 1 follow-up and reported enco...

WESTBOROUGH, Mass.--(BUSINESS WIRE)--New real-world data demonstrates low ACL retear rates and clinically meaningful improvements following ACL restoration with the BEAR Implant....

SAN FRANCISCO--(BUSINESS WIRE)--ClinPro Trials (CPT), The Compliance CRO™, today announced its independent clinical compliance assessment service for biopharmaceutical sponsors, boards, and investors. While sponsors routinely delegate trial activities to operational CROs, ultimate responsibility for data integrity remains with the sponsor. Operational reporting often tracks milestone progress without providing an independent view of the compliance state across the entire trial. If compliance ga...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) of its Phase 2 HARMONIC™ trial of LP-300. The Taiwan Food and Drug Administration (TFDA) approved the amended protocol earlier in September, and the lead Taiwan site received local Institutional Review Board (IRB) approval on September 29, 2026. The lead site is now open to...